INMED PHARMACEUTIC (OTCMKTS:IMLFF)
INMED PHARMACEUTIC (OTCMKTS: IMLFF) gained 13.9% as investors took note of the company’s industry’s first, cannabinoid biosynthesis program. The new process has the potential to produce cannabinoids at scale, which should allow for industrial manufacturing of naturally occurring cannabinoids.
InMed Biosynthesis Program
Investors continue to push the stock higher in the market because the process has the potential to address some of the challenges that face the industry. The stock is currently closing in on its 52-week high of $0.62 after gaining more than 100% in market value since the start of the year. For the full year, the stock is up by more than 200%.
The process of extracting and purifying cannabinoids has turned out to be extremely costly and time-consuming. However, if INMED PHARMACEUTIC (OTCMKTS:IMLFF) biosynthesis process is anything to go by, the challenges could be a thing of the past.
INMED PHARMACEUTIC (OTCMKTS:IMLFF), Biosynthesis program has the potential to be a game changer and a possible replacement for the current plant-based extraction methods. The process has already proved to be effective in producing multiple gateway cannabinoids, using genetically engineered microorganisms. Produced molecules can be functionalized to produce 90+ downstream cannabinoids found in the cannabis plant.
“The company’s biosynthesis process results in pharmaceutical grade (>95%) purity and is bio-identical to the plant’s cannabinoids. Importantly, by making individual cannabinoid compounds, InMed can avoid any contamination by tetrahydrocannabinol (THC) and, therefore, InMed products will have no psychoactive properties,” INMED PHARMACEUTIC (OTCMKTS:IMLFF) in a statement.
Biosynthesis Program Synergies
The new biosynthesis process could address the U.S. Food and Drug Administration’s (FDA) concerns with regards to how drugs are extracted from Marijuana. The process should give manufacturers the ability to produce high-quality and consistent active ingredients every time. It should also eliminate concerns of crop variability and pesticide contaminants, while greatly reducing cost.
The biosynthesis process positions INMED PHARMACEUTIC (OTCMKTS:IMLFF) among the ranks of big companies that are developing proprietary synthetic cannabinoid treatments for transdermal delivery. The company has already used the new process in the ocular market.
The InMed-UBC study becomes the first ever to report hydrogel-mediated cannabinoid nanoparticle delivery to the eye. Study results indicate enhanced drug uptake via the cornea and lens, further validating the company’s capacity to conduct a wide spectrum of drug development activities.
I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.
Don’t miss out! Stay informed on $IMLFF and receive breaking news on other hot stocks by signing up for our free newsletter!